Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines
Combined measles-mumps-rubella (MMR) vaccines produced by GSK (GSK-MMR) and Merck (Merck-MMR) have demonstrated effectiveness and an acceptable safety profile, as documented over decades of post-licensure use in various regions worldwide. In the United States, 2 doses of the MMR vaccine are recommen...
Main Authors: | Md Ahsan Habib, Michael Povey, Giacomo Casabona, Tina Singh, Remon Abu-Elyazeed |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-01-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2023.2188852 |
Similar Items
-
Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context
by: Giacomo Casabona, et al.
Published: (2023-12-01) -
Immune response to co-administration of measles, mumps, and rubella (MMR), and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina
by: Carla Vizzotti, et al.
Published: (2023-03-01) -
Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin
by: Andrea A. Berry, et al.
Published: (2017-07-01) -
Intralesional measles–mumps–rubella is associated with a higher complete response in cutaneous warts: a systematic review and meta-analysis of randomized controlled trial including GRADE qualification
by: Rachel Vania, et al.
Published: (2021-11-01) -
Utility of serological screening for measles, mumps and rubella in immunocompromised patients
by: L Sticchi, et al.
Published: (2019-12-01)